Talphera (NASDAQ:TLPH) Shares Up 4.5% – Should You Buy?

Talphera, Inc. (NASDAQ:TLPH)’s share price traded up 4.5% during trading on Thursday . The stock traded as high as $0.8406 and last traded at $0.80. 126,395 shares changed hands during mid-day trading, a decline of 4% from the average session volume of 131,947 shares. The stock had previously closed at $0.7652.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Talphera in a research note on Monday, April 20th. Westpark Capital initiated coverage on Talphera in a report on Thursday, April 30th. They issued a “buy” rating and a $3.00 price objective on the stock. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Talphera presently has a consensus rating of “Hold” and a consensus price target of $3.00.

Talphera Trading Up 4.5%

The stock has a market cap of $41.52 million, a PE ratio of -2.58 and a beta of 0.76. The company has a fifty day moving average of $0.81 and a 200-day moving average of $0.95.

Talphera (NASDAQ:TLPH) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.03.

Insider Activity

In other news, CEO Vincent J. Angotti acquired 213,310 shares of the business’s stock in a transaction that occurred on Friday, March 13th. The shares were purchased at an average price of $0.59 per share, for a total transaction of $125,852.90. Following the acquisition, the chief executive officer owned 800,705 shares of the company’s stock, valued at $472,415.95. This represents a 36.31% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 3.50% of the company’s stock.

Institutional Investors Weigh In On Talphera

Several large investors have recently bought and sold shares of TLPH. Rosalind Advisors Inc. increased its holdings in Talphera by 118.9% during the 3rd quarter. Rosalind Advisors Inc. now owns 4,385,757 shares of the company’s stock worth $3,917,000 after purchasing an additional 2,381,818 shares during the period. Nantahala Capital Management LLC increased its holdings in Talphera by 75.3% during the 3rd quarter. Nantahala Capital Management LLC now owns 3,492,519 shares of the company’s stock worth $3,120,000 after purchasing an additional 1,500,000 shares during the period. Empery Asset Management LP purchased a new stake in Talphera during the 4th quarter worth about $1,520,000. Cantor Fitzgerald L. P. purchased a new stake in Talphera during the 4th quarter worth about $658,000. Finally, Renaissance Technologies LLC increased its holdings in Talphera by 412.6% during the 4th quarter. Renaissance Technologies LLC now owns 257,380 shares of the company’s stock worth $293,000 after purchasing an additional 207,166 shares during the period. Hedge funds and other institutional investors own 37.67% of the company’s stock.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.